secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001708599-26-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman
--------------------------------------------------------------------------------

- First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
- Pricing at $2.25 per share (68% premium to March 17 close); 50% warrant coverage at $5 exercise (273% premium).
- Warrants if fully exercised could add up to $33.3M; total potential funds ~$63.3M to extend runway into 2H 2027.
- Proceeds to fund SER-252 registrational trial for advanced Parkinson's; first patient dosed in SAD study.
- Greg Bailey, M.D., lead investor, appointed Co-Chairman of Board; existing convertible note amended to eliminate further borrowing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/ser-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer